Bence Ferencz, Klára Török, Orsolya Pipek, János Fillinger, Kristóf Csende, András Lantos, Radoslava Černeková, Marcel Mitták, Jozef Škarda, Patricie Delongová, Evelyn Megyesfalvi, Karin Schelch, Christian Lang, Anna Solta, Kristiina Boettiger, Luka Brcic, Jörg Lindenmann, Ferenc Rényi-Vámos, Clemens Aigner, Judit Berta, Zsolt Megyesfalvi, Balázs Döme
BACKGROUND: Advancements in immunotherapeutic approaches only had a modest impact on the therapy of lung neuroendocrine neoplasms (LNENs). Our multicenter study aimed to investigate the expression patterns of novel immunotherapy targets in intermediate- and high-grade LNENs. METHODS: The expressions of V-domain Ig suppressor of T cell activation (VISTA), OX40L, Glucocorticoid-induced TNF receptor (GITR), and T cell immunoglobulin and mucin domain 3 (TIM3) proteins were measured by immunohistochemistry in surgically resected tumor samples of 26 atypical carcinoid (AC), 49 large cell neuroendocrine lung cancer (LCNEC), and 66 small cell lung cancer (SCLC) patients...
May 2, 2024: Cancer Immunology, Immunotherapy: CII